Gout Therapeutics Market (Drug Type: NSAIDS, Colchicine, Corticosteroids, Urate-lowering Drugs, and Biologics)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Gout Therapeutics market size was estimated at USD 2.9 billion in 2021 and is expected to surpass around USD 4.15 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 8.8% during the forecast period 2022 to 2030.

Gout is an inflammatory arthritic condition caused by the deposition of monosodium crystals (MSU) into the distal joints and peripheral tissues. Gout is a common form of inflammatory arthritis that is quite painful. It usually affects one joint at a time (often the big toe joint). There are times when symptoms get worse, known as flares, and times when there are no symptoms, known as remission.

Gout is a common and complex form of arthritis that can affect anyone. It is characterized by sudden, severe attacks of pain, swelling, redness, and tenderness in one or more joints, most often in the big toe. It usually occurs earlier in men than women. It generally occurs after menopause in women. Men can be three times more likely than women to get it because they have higher levels of uric acid most of their lives. Women reach these uric acid levels after menopause.

Gout treatment exist; however, therapy should be tailored for each person. Treatment choices depend on kidney function, other health issues, personal preferences, and other factors. Patients could need medications to lower their elevated blood uric acid levels that predispose to gout. Over time, increased uric acid levels in the blood could lead to deposits of urate crystals in and around the joints. These crystals can attract white blood cells, leading to severe, painful gout attacks and chronic arthritis.

Report Scope of the Gout Therapeutics Market

Report Coverage

Details

Market Size

USD 4.15 Billion by 2030

Growth Rate

CAGR of 8.8% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year

2021

Forecast Period

2022 to 2030

Segments Covered

 Drug Type, Distribution Channel and Region,

Companies Mentioned

  •  AstraZeneca
  • Hikma Pharmaceuticals plc
  • Horizon Pharma plc.
  • Iroko Pharmaceuticals, LLC
  • Merck & CO., Inc.
  • Mylan N.V.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited,
  • Teijin Pharma Limited.
  • Teva Pharmaceutical Industries Ltd.

 

Increase in Incidence of Gout Propelling Global Gout Therapeutics Market

Gout is the most common type of inflammatory arthropathy. According to several studies, its prevalence and incidence have increased in the last few decades. Hyperuricemia, genetic factors, dietary factors, alcohol consumption, metabolic syndrome, hypertension, obesity, diuretic use, and chronic renal disease are the risk factors for the development of gout.

Several studies have shown that gout management in primary care is suboptimal, which could contribute to rise in prevalence of clinically significant symptomatic gout. Obesity, diabetes, and hypertension were found to be common in gout patients in the U.K. and Germany. Age is also a risk factor; hence, population aging is likely to increase the incidence of gout. Complex cases of gout, particularly secondary gout, are becoming more common in hospital practice, with the rising prevalence of advanced chronic kidney disease and usage of diuretics and nephrotoxic drugs potentially driving the global gout therapeutics market size.

Gout incidence and prevalence increases with age, with prevalence reaching 11% to 13% and incidence reaching 0.9% in people over the age of 80. Gout is more common in racial minorities in the U.S., New Zealand Mori, Han Chinese, and some ethnic groups in Asia Pacific.

Rise in Need to Reduce Inflammation and Pain in Joints Augmenting Nonsteroidal Anti?inflammatory Drugs (NSAIDs) Segment

In terms of drug type, the nonsteroidal anti?inflammatory drugs (NSAIDs) segment accounted for the largest gout therapeutic market share in 2021. NSAIDs are aspirin-like medications that can reduce inflammation and pain in joints and other tissues. NSAIDs, such as indomethacin (Indocin) and naproxen (Naprosyn), have become the treatment of choice for the majority of acute gout attacks. There is no evidence that one NSAID is superior to another. High doses of short-acting NSAIDs provide the quickest symptom relief. These medications could cause stomach upset, ulcers, or diarrhea; however, most people tolerate them well when used for a short period of time.

Urate-lowering drugs are utilized for the symptomatic treatment of gout arthritis, as a first line of therapy or in combination therapy. According to estimates, more than 2 million people in the U.S. take medication to decrease serum uric acid levels. Moreover, higher penetration of urate-lowering drugs compared to biologics into the gout therapeutics market for the treatment of people suffering from chronic or acute gout diseases propels the antihyperuricemic agents (urate-lowering drugs) segment.

Increase in Geriatric Population with Moderate to Severe Gout Arthritis Propelling Hospital Pharmacies Segment

Based on distribution channel, the hospital pharmacies segment is projected to account for a dominant share of the global gout therapeutic market in 2021. The segment is anticipated to grow considerably from 2022 to 2031. Hospital pharmacies is expected to be the second-leading segment, in terms of market share, during the forecast period. The segment's large market share is attributed to the increase in geriatric population with moderate to severe gout arthritis requiring hospital pharmacy to purchase drugs.

The online pharmacies segment is likely to grow at a rapid pace during the forecast period. Increase in the number of online pharmacies and acceptance of several gout therapeutics as over-the-counter drugs in medical therapy to penetrate the pharmaceutical and the health care market are projected to augment the online pharmacies segment.

Regional Outlook of Global Gout Therapeutics Market

North America accounted for the largest share of the global gout therapeutics market in 2021. The region is projected to be a highly lucrative market during the forecast period, with high market attractiveness index. Increasing incidence of gout and rising burden of comorbidities in the U.S. are likely to propel the market in the region during the forecast period. Gout is the most common inflammatory arthritis in the country. Several studies have shown an increase in prevalence in the last few decades. There are more than nine million gout patients, and nearly a third of those patients are treated with oral urate-lowering therapies in the past 20 years. The number of people living with gout-related disability has risen steeply in the past few years.

The market in Asia Pacific is expected to grow at a rapid pace from 2022 to 2030. The incidence and prevalence of gout have been steadily increasing in the region, which has resulted in increased research & development activities in gout diagnosis and gout treatment.

Analysis of Key Players in Global Gout Therapeutics Market

The global gout therapeutics market is consolidated, with the presence of small number of leading players. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the leading players in the global gout therapeutics market. Takeda Pharmaceutical Company Limited, Teijin Pharma Limited, Novartis AG, Mylan N.V., MERCK & Co. Inc., Iroko Pharmaceutical LLC, Hikma Pharmaceuticals plc, Horizon Therapeutics plc, and Teva Pharmaceutical Industries Ltd. are the prominent players operating in the global gout therapeutics market.

Key Developments in Global Gout Therapeutics Market

  • In August 2022, Synlogic, Inc., a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases using its proprietary synthetic biology approach, announced the development of a new drug candidate for the treatment of gout in collaboration with Ginkgo Bioworks, a leading horizontal platform for cell programming
  • In July 2022, Horizon Therapeutics' supplemental Biologics License Application (sBLA) for the Krystexxa (pegloticase) injection, given in conjunction with methotrexate, to help uncontrolled gout patients achieve a complete response to treatment received approval from the U.S. Food and Drug Administration (FDA).
  • In June 2021, Arrowhead Pharmaceuticals, Inc. and Horizon Therapeutics plc announced a global collaboration and license agreement for ARO-XDH, a previously unknown discovery-stage investigational RNA interference (RNAi) therapeutic being developed by Arrowhead as a potential treatment for uncontrolled gout

Some of the prominent players in the Gout Therapeutics Market include:

  • AstraZeneca
  • Hikma Pharmaceuticals plc
  • Horizon Pharma plc.
  • Iroko Pharmaceuticals, LLC
  • Merck & CO., Inc.
  • Mylan N.V.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited,
  • Teijin Pharma Limited.
  • Teva Pharmaceutical Industries Ltd.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Gout Therapeutics market

  • Drug Type
    • NSAIDS
    • Colchicine
    • Corticosteroids
    • Urate-lowering Drugs
    • Biologics
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

By Geography

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • United Kingdom
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Rest of Latin America

Middle East & Africa (MEA)

  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Gout Therapeutics industry analysis from 2022 to 2030 to identify the prevailing Gout Therapeutics industry opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global Gout Therapeutics industry segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global Gout Therapeutics industry trends, key players, market segments, application areas, and market growth strategies.

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers